Strategic Focus Amphista Therapeutics is advancing next generation targeted protein degradation (TPD) platforms with a focus on non-cereblon/non-VHL mechanisms and orally bioavailable degraders, presenting opportunities to partner on preclinical and translational collaborations that expand beyond conventional degradation paradigms.

Clinical Momentum Recent leadership appointments and IND filing preparations for AMX-883 indicate a move toward clinical development and potential co-development or funding discussions around BRD9 degraders and SMARCA2 degraders in SMARCA4-mutant NSCLC.

Key Programs Lead programs AMX-883 BRD9 degraders and SMARCA2 degraders are generating preclinical data and conference visibility (ASH and AACR), signaling near-term opportunities for partnering in IND-enabling work, biomarker strategies, and potential licensing.

Investment Readiness Funding model described as collaboration-led suggests openness to strategic partnerships, grants, or venture co-funding to accelerate discovery, IND filing, and early-phase clinical development.

Market Positioning As a Cambridge-area biotech with a pedigree from Advent Life Sciences and Alessio Ciulli’s group, Amphista is positioned to attract collaborations with biotech and pharma seeking access to innovative TPD modalities, particularly in oncology indications with high unmet need.